Context: Randomized trials show that low-dose (1.1 GBq [30 mCi]) radioiodide (RAI) has
efficacy equivalent to high-dose RAI (3.7 GBq [100 mCi]) in thyroid remnant ablation (TRA) …

Objective Is to investigate possible factors predicting success of ablation for 3700 MBq
radioactive iodine 131 in patients with differentiated thyroid cancer (DTC) following near …

(1) Background—low-dose radioiodine ablation is an accepted strategy for the treatment of
low-and intermediate-risk thyroid carcinomas, although there is no international consensus …

Objective: Remnant ablation with radioactive iodine (I-131) is a successful form of treatment
that aims to destroy the remaining residual tissue and/or metastatic tissue after total …

Background In differentiated thyroid cancer (DTC) patients at intermediate risk of
recurrences, no evidences are provided regarding the optimal radioactive iodine (RAI) …

Objective (a) To compare the efficacy of low-activity (2 GBq; 54 mCi) 131I ablation using l-
thyroxine withdrawal or rhTSH stimulation, and (b) to assess the influence of thyroid …

Objective Postoperative radioiodine remnant ablation (RRA) represents an adjunctive
therapeutic modality in patients with differentiated thyroid cancer (DTC). The impact of late …

Objectives Currently, little is known about the prognostic significance of achieving successful
ablation with the first dosage of I-131 in patients with differentiated thyroid cancer. This study …

Aim: Based on the response criteria of the 2015 American Thyroid Associations guidelines,
our objectives were to determine the response rate when using a low dose of 131-I GBq in …

Objective To examine success rates in strictly defined high‐risk differentiated thyroid cancer
(DTC) patients who received a high‐activity (≥ 5550 MB q) adjuvant postoperative I‐131 …